The Cell & Gene Therapy Manufacturing Pathway: Part 1

CELL AND GENE THERAPY INSIGHTS

March 2016

The Cell & Gene Therapy Manufacturing Pathway: Part 1

Download PDF

Foreword

Spotlight on the cell & gene therapy manufacturing pathway

Spotlight on the cell & gene therapy manufacturing pathway

Chris Mason, Elisa Manzotti

Expert Insight

Evolving product attributes through the lens of MSC translation

Evolving product attributes through the lens of MSC translation

Drivers and methodologies for making cell therapy process changes

Drivers and methodologies for making cell therapy process changes

Gregory Russotti

Centralized or decentralized manufacturing? Key business model considerations for cell therapies

Centralized or decentralized manufacturing? Key business model considerations for cell therapies

Nicholas Medcalf

Cell and gene therapy manufacturing: the necessity for a cost-based development approach

Cell and gene therapy manufacturing: the necessity for a cost-based development approach

S Callens, J Hasan, R McCoy et al.

Perspective

Toward a scalable and consistent manufacturing process for the production of human MSCs

Toward a scalable and consistent manufacturing process for the production of human MSCs

Key considerations in optimizing pluripotent stem cell bioprocessing

Key considerations in optimizing pluripotent stem cell bioprocessing

Innovator Insight

Translational cell & gene therapy collaborations: accelerating time to market

Translational cell & gene therapy collaborations: accelerating time to market